ODP Early-Stage Investigator Lectures Set
NIH’s Office of Disease Prevention will host two Early-Stage Investigator Lectures.
On Wednesday, Apr. 28 at 11 a.m. ET, Dr. Morgan M. Philbin, assistant professor, sociomedical sciences, Columbia University Mailman School of Public Health, will present “The Social Side Effects of Biomedical HIV Technologies: Facilitating the Roll-Out of Long-Acting Injectable ART and PrEP.”
Philbin will discuss current research on long-acting injectable antiretroviral therapy (ART) and HIV pre-exposure prophylaxis (PrEP) with a focus on the multilevel barriers and facilitators to successful implementation. She will also highlight key points that must be addressed to scale up biomedical HIV technologies—in ways that maximize population health impact and reduce existing disparities—related to current formulations of PrEP and ART. Her research has been funded by several institutes, including the National Institute on Drug Abuse, the National Institute on Minority Health and Health Disparities, the National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health.
On Wednesday, May 5 at 11 a.m. ET, Dr. Stephen Juraschek, assistant professor of medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, will present “Dietary Patterns to Prevent Cardiovascular Disease.”
Juraschek will describe novel evidence in support of healthy dietary patterns to prevent mechanisms of subclinical cardiovascular damage. He will also discuss the status of healthy eating and opportunities to enhance adoption of healthy eating in the United States. His research has been funded by the National Heart, Lung, and Blood Institute, the National Institute on Aging and NIMHD.
Registration is required. Use this link: prevention.nih.gov/news-events/early-stage-investigator-lecture/2021-awardees. Lectures will be recorded and available on the ODP website approximately 1 week after each session.
ODP Early-Stage Investigator Lectures recognize early-career prevention scientists who have not yet competed successfully for a substantial NIH-supported project, but who have already made outstanding research contributions to their respective fields and are poised to become future leaders in prevention research.